AMSTERDAM — Norucholic acid (NCA), an investigational therapy, demonstrated significant superiority over placebo in halting disease progression in patients with primary sclerosing cholangitis ...

British boxer Georgia O’Connor, 25, tragically passed away after a battle with cancer, which she believed stemmed from her ulcerative colitis and prim ...

in primary sclerosing cholangitis (PSC) 1 was presented in an oral Distinguished Abstract Plenary session at Digestive Disease Week ® (DDW 2025) in San Diego, California. Paul J. Pockros ...

Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of ...

There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam.

In a groundbreaking achievement, King's College Hospital London in Dubai has successfully performed the UAE's first split ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...

1 CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients wit primary ...